Assuming the availability of a good intensive care unit and effective outpatient care, successful transplantation of any whole organ rests on five specific laboratory-based principles: surgical technique; preservation technology; considerations of histocompatibllity; immunosuppression; and, least appreciated, the incidental induction of varying degrees of donor-specific nonreactivity (tolerance), without which none of our organ recipients could be rehabilitated for long. Traditionally, the last three of these considerations have been discussed separately. However, the discovery in 1992 that all patients bearing long surviving organ allografts had donor leukocyte chimerism 8o • 81 and the realization that this must be accomplished for successful xenotransplantation 96 has made such a reductionist approach obsolete. Consequently, the first section of this chapter will describe the interrelation of his to. compatibility, immunosuppression, and tolerance. The last cwo sections will briefly discuss organ preservation and the limitations of clinical tissue matching. Expositions of surgical technique can be found in organ-specific chapters.
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THE IMMUNOLOGIC BARRIER
The modern evolution of clinical transplantation of whole organs has spanned 40 years. This evolution has involved some of the most remarkable and conceptually enigmatic developments in the hiscory of medicine. Successful engraftment of the kidney,50 liver,84 hearc,9 lung,23 pancreas,36 intestine,31 and multiple abdominal viscera 94 was a cumulative achievement. largely accomplished by dogged trial and error. Each organ-defined specialty has had historians who track their story back to one of the foregoing milescones where the trail goes cold. The reason is that such accounts are preoccupied with a succession of events rather than the biologic principles that apply to all organ aIloAided by Research Gr.anrs front .h~ Vctcr.ans Adnlinistndon and Prujn:r Gr.uu Nu. DK29%21 from rhe N.ri" ... 1 InSlirurn "f Halrh. Ikthnd •. Maryl.nd.
TRANSPLANTATION
grafts. This was understandable because there was no rational reason co expect that a transplanted histoincompatible organ could breach the seemingly inviolate barrier of immunologic reactivity using the treatment formulas that became standard. When this proved feasible. the inability to explain why caused an ever-increasing number of clinical transplant surgeons and physicians to regard basic immunology as an interesting hobby, irrelevant to their practice.
The Beguiling Identical Twins
The potential benefit of whole organ replacement in the absence of an immune barrier was dramatically demonstrated with the identical cwin kidney transplantation performed in December 1954 by Murray49 (Nobel Laureate, 1990 ). Although symbolically important, this achievement only confirmed what already was known to be possible with identical cwin skin grafts. 49 Seven years later, the Nobel Laureate (1960), Burnet l6 reported in The New EnglAnd Journal of Medicine that" ... much thought has been given to ways by which tissues or organs not genetically and antigenetically identical with the patient might be made to survive and function in the alien environment. On the whole, the present oudook is highly unfavorable to success .... n The One-Way Paradigm
Rejection
What was the genetically determined barrier? AJthough it has never been precisely defined, there was little mystery after 1944 about the general meaning of rejection after its elucidation by Medawar~6 (co-Nobel Laureate with Burnet, (960) as an immunologic event. This great contribution created the indelible image that a tissue (or organ) allograft was an island in a hostile recipient sea ( Fig. 35-1, A) .
Tolerance
In contrast, why allografts or xenografts could escape from rejection without crippling the recipient with immunosuppression (Fig. 35-1. 11) . Thereafter. the mice failed to recognize donor strain skin grafts or other tissues as alien (a concept known as acquired tolerance). The switch in immunologic apparacus was consistenc with the definition of transplantation immunology in terms of a unidirectional immune reaction (the "one-way paradigm"). 
Graft-versus-host disease
[t was recognized as early as 1957 in mouse l2 and chicken models 70 that an immunologically active graft could turn the tables and reject the recipient. using a complete genetically controlled repertoire of immune reactivity similar to that of the recipient. This was called graft-versus-host disease (GVHD). or alternatively "runt disease". If the host was immunologically defenseless. the risk for this disease was approximately proportional to the extent of the major histocompatibility complex (MHC) difference between donor and recipient. Such disparities became measurable serologically in humans after identification of the HLA antigens by Dausset 21 (Nobel Laureate, 1980) , T erasaki, 101 and others whose reminiscences have recently been collected. For many years, the complication of GVHD in rodent llO and large animal irradiation chimera models 3M I.60.,o5 forestalled the clinical use of HLA-mismatched bone marrow cells or other mature immunocytes both for immunologic reconstitution with purely hematologic objectives and as a means of facilitating whole organ graft acceptance.
Clinical bone marrow transplantation
The strategy that eventually made possible clinical bone marrow transplancation in 1968 was a straightfotward extension of the rodent experiments with similar histocompatibility-imposed restrictions.~·2.,. 44 After recipient cytoablation with total body irradiation or cytotoxic drugs (see Fig. 35-1. 11) . stable chimerism could be induced in humans by the infusion of donor bone marrow if there was a good HLA match. Otherwise. ;111 intolerable incidence of lethal GVHD occurred. At varying times after successful engraftment. maintenance immunosuppression was frequently not needed. mimicking the kind of acquired immunologic tolerance originally described by Billingham et al l . I . 14 ;\Ild then Main and Prehn. '" 
Clinical organ transplantation

Total body irradiation
The accomplishment of clinical bone marrow transplantation eFfectively detached from a scicmilic ba.~e surgeons and physicians who by this time had recorded many successful human whole organ transplantations (mosdy kidneys) under cominuous immunosuppression without either dependence on H LA matching or the complication of CVHD. Most immunologists were dumbfounded by these successes.
Host preconditioning played a hismrically important role in the first six successful renal transplantations (defined as survival for more than 1 year) between 1959 and 1962-one in Boston ~(I and five in France .. n .. 1H The recipients were prepared for operation with sublethal mtal body irradiation but without donor bone marrow. Theil 0wn bone marrow recovered, and one of these patients (in Paris) survived for 26 years; however. these were isolated successes in a sea of failures. and pessimism set in worldwide about the prospects of moving forward.
Chemical immunosuppression
The frustration continued after the introduction for human renal transplantation of 6-mercaptopurine (6-MP) and its analogue. azathioprine. following extensive experimental studies. first with rodent skin transplantation 47 
The drug cocktail breakthrough
When azathioprine was combined with prednisone in 1962-63. 90 the tidal wave of whole organ cases began in earnest. A characteristic cycle of convalescence was identified in which kidney rejection could be reversed surprisingly easily with prednisone. More important, the later need for maintenance immunosuppression frequently declined as if the immune barrier had been lowered ( Fig. 35-2) ; and in occasional cases therapy could be stopped. The same sequence has been seen since with all other org.ms transplanted and with all of the two-drug and more complex multiple agent immunosuppressive regimens. Drugs introduced later were more potent and reli;\ble in chaperoning the desired chain of events: antilymphocyte globulin (ALG).II" cyclosporine. I Immune Reaction o of increasingly sophisticated cellular and ultimately molecular studies of unidirectional immunologic reactions. The resulting plethora of new information resembled at times the entries in an exponentially expanding phone book. Most seriously, the flawed context lured successive generations of investigators into the trap of believing that tolerance induction for whole organ recipients (the "holy grail") lay in variations on the HLA-limiting strategy that was used for bone marrow transplantation. This strategy included host preconditioning in preparation for various donor leukocyte preparations.
Cell-mediated immunity
By the early 1970s, most virologists and basic immunologists who were attempting to understand organ rejection shifted their efforts from whole animal studies to the T Iymphocyte-oriented cell culture (i.e., in vitro) systems. These labors were rewarded by a Nobel Prize (Baruj Benacerraf. 1980) and the Lasker Prize in Basic Science of 1995, which was shared by four Americans and one SwiSS.21.112.117 The conceptual model that emerged from these srudies provided an explanation of cell-mediated immunity ( Fig. 35-3 ). In the context of the one-way paradigm, the details of the allogeneic reaction (i.e., rejection) included its dependence on antigen-presenting cells, the necessity for a costimularory molecule(s) (the two-signal concept of self/nonself-discrimination), the important role of accessoty molecules, and cytokine control of clonal expansion of T-helper lymphocytes as well as of the cytotoxic T cells that arc the agents of allograft destruction. The bewildering mass of details (0 which thousands of investigators had contributed over a 3-decade period had long since overwhelmed most clinicians interested in applying the new information.
In the meanwhile. rhe surprising diversity had been documented of agents with which long-term or permanent graft survival could be indllced with a short course of therapy. regardless of the level at which the ;Igent illlervenes in the immune reaction I"'. (Fig. 35-3 ). I>eoxyspergllalin was believed to alter 
The Two-Way Paradigm Whole organ transplantation
Insight into what was happening to the pioneer organ recipients was obtained in retrospect by studies at the University of Pirrsburgh nearly 30 years later of a group of kidney and liver recipients who were still extant from the earliest clinical trials at the University of Colorado. Donor leukocytes of bone marrow origin ("passenger leukocytes"71.?), which are parr of the mucture of all complex grafts, were found to have migrated from the organs and survived ubiquitously in the patients for up (0 3 decades. Ho . HI Thus, organ allograft acceptance was associated with the cryptic persistence of a small fragment of extramedullary donor marrow, including stem cells (depicted as a bone silhouette in Fig. 35-1, C) . These cells had been assimilated into the overwhelmingly larger immunologic network of the host. The leukocyte movement occurred in both directions. with a small number of residual donor leukocytes (microchiIllerism) in both the graft and host.
From this information, a revision of transplantation imIIll1nology was possible in which the immunologic confrontation I(lilowing whole organ transplantation could be seen as a Fig. 35-4) , providing the two participants in the David/Goliath mismatch could survive the initial confrontation. Clinically, but not in several animal models. such survival requires an umbrella ofimmunosuppression that protects both cell populations equally (see Fig. 35-1. C) . Understanding the amplication device by which a small number of donor cells can so profoundly affect the immunologic vision of the vast recipient army against which it is arrayed is of intense scientific inreres[. The chimeric leukocytes are multilineage. 22 .~II.II11.II' However. the anrigen-presenting dendritic cells (DCs) of Steinman and Cohn')7.')11 are believed [0 be key [0 the reciprocal tolerogenic process bec.1use they can modify. in both cell populations. the expression of cell inreraction. MHC, and adhesion molecules-all of which determine how antigen signals arc heeded by T cells."?
Historical enigmas With thc two-way paradigm. the reason for virtually every previously unexplained experimenral or clinical observation after whole organ transplantation became either transparent, or at least susceptible to experimental inquiry.Hu.H' It could be understood why organ grafts arc inherendy tolerogenic, why HLA matching is so poorly predictive of outcome, and why GVHD does not develop after the transplantation of immunologically active grafts (such as the liver and intestine) or as it w~ soon learned, even of bone marrow providing the recipient immunologic system is left intact.
With the two-way mutual cancellation implicit in this concept, the loss or blunting of an HLA-matching effect is easy (0 understand. With each further level of histoincompatibiliry. the reciprocal effect apparendy escalatcs both ways under the umbrella of effective immunosuppression (Fig. 35-5 ). The consequent dwindling of the matching effect as donor-specific and recipient-specific nonreactiviry evolves accounts for "blindfolding" of the expected HLA influence.
In addition to explaining why the HLA matching effect is mitigated. the mutual functional cancellation of the two cell populations explains why GVHD does not develop after liver, intestinal, multivisceral, and heart-lung transplantation. despite the he:avy lymphoid content of those organs.
Augme:ntation of spontaneous chimerism Because acquisition of immunologic tOlerance in the BillinghamBrent-Me:dawar and derivative modc:ls depended on donor leukocyte: (splenocyte: or bone marrow) infusion,I3·14.40 sporadic anempts have been made to improve organ allograft outcome by infusing adjuvant donor bone marrow8.S1 or blood. 3 • 64 . 72 These were hampere:d in design or execution by the: assumption that the infused cells would be destroyed unless there were recipient preconditioning with irradiation or myelotoxic drugs.
In rum, the prospect of recipient cytoablation engendered justifiable anxiery about causing GVHD. The appropriate timing of the cell infusions was also controversial. Consequently, this strategy never gained a clinical foothold.
The information that emerged in 1992 indicating that leukocyte chimerism is a naturally occurring event after whole organ transplantation 8o . 81 exposed a perioperative window of opportunity during which unaltered HLA-incompatible bone marrow or donor-specific blood transfusion were predicted to be safe without recipient preparation or any deviation from the generic noncytoablative practices of immunosuppression for whole organ transplantationrhat had evolved over the years from the original prednisone/azathioprine formula.'X)
The validiry of this strategy was verified recently in nonpreconditioned recipients of cadaveric kidneys. livers. hearts. and lungs who were given 3 (0 5 X 10~/kg adjuvant bone marrow cells during organ transplantation under standard tacrolimusprednisone treatmenr (Fig. 35-6 ).l~ Chimerism estimated (0 be more rhan 1000 times that which occurs in conventional whole organ recipients was produced and sustained reliably and safely. The persistent blood chimerism (usually> 1%), trend toward donor specific nonreactiviry, and high rate of patient and graft survival has marked these bone marrow-augmented recipients as an advantaged cohon. These patients are the first to undergo HLA-mismatched cadaveric organ transplantation with the hope of eventually becoming drug free. The process of tolerance induction and drug weaning is expected to take 5 to 10 years; and, in some the drug free state may never be arrainable.
The drug-free state
The concept that organ transplantation is equivalent to a small bone marrow transplantation (and that this explains allograft acceptance) has gone well beyond a hypothesis. The human phenomenology has been confirmed and gready extended in animal models. principally by Qian et al,s8 Murase et al. 52 and Demetris et al. 22 The cardinal principle revealed by the clinical and animal studies is thae ehe long and continuing survival of an organ allograft means by definition that donor leukocyte chimerism is present. Failure to demonstrate chimerism in such recipients connotes an inadequate search. 52 Does chis mean chat chimerism is synonymous with tolerance? Of course not. Donor leukocyte chimerism is merely a prerequisite for graft acceptance. 80 Is the demonstration of chimerism an indication to Stop immunosuppression? This shockingly naive question has been asked of us dozens of times. even by experienced clinicians. The answer is "No"! However.
knowledge of the chimerism mechanism makes it clear why drugs can be stopped permanendy after organ transplantation
In some cases.
In early 1992, we formally reevaluated 43 liver recipients who had received the transplant 10 to 23 years previously.sl More than half of the recipients had been infants or children at the time of their operation. Five (12%) of the 43 were already off drugs at that time, and had been for 1 to 15 years. Since then, one of the 43 long survivors died from recurrent hepatitis S, leaving 42 survivors in October 1995. During the 3.5 intervening years, seven more of these recipients came off of drugs. Thus. the incidence of drug freedom in this bellwether cohon of liver recipients, who represent approximately 80% of the longest survivors in the world after this procedure. is 12 of 42 or 28%. The nearly equal cumulative duration of these 12 patients off of immunosuppression (coded grey) and under treatment (shown in black) is evident in Figure 35-7 .
Complementing the foregoing observations. Ramos et al S9 have reponed a prospective weaning erial for liver recipients. limited for ehe mose pan to paeients who were 5 to 10 years pose-transplantation. Freedom from rejection for at least 5 years was a prerequisite. Since the first repon, the trial has expanded to 80 patients ( Fig. 35-8 ). Forry-four (55%) of these liver recipients have come otT drugs completely or have moved uninterruptedly in that direction. In 22 patients whose weaning is complete, the drug-free rime averages 2.5 years. Weaning is now being done more slowly than at rhe beginning of the trial be- cause of a 30% incidence of rejection (see Fig. 35-8) . It was evidem that most of the 80 liver recipiems had been at a level of immunosuppression higher than they needed.
The foregoing trial did not include cases in which immunosuppression was sropped because of life-threatening infections. Ten pediatric liver recipients whose drugs were discontinued permanently as early as 6 months after transplantation because of Epstein-Barr virus (EBV). associated B-cell lymphomas. human immunodeficiency virus (HIV). or hepatitis C virus are listed in Table 35 -1.(·2 After an average drug-free period of more than 4 years. eight (80%) of these 10 patienrs remain drug free and healthy. including 5 of the 6 patiems whose EBV-associated B cell lymphomas (also called posmansplant Iymphoproliferative disorders IPTLDsJ) melted after drugs were sropped. The demollstr;uioll that these tumors respond to immUllomodulatioll has been the most reproducible example of cancer imrnunosurveillance ever reported c1inically. 'J2 It is more dangerous to attempt weaning after kidney transpiamatio/l, and we rarely recommend this. However. five of our longest-surviving living related kidney recipients (the first five listed in Table 35 -2) have heen ofr of all immunosuppression for 2 10 30 years. The first ,lIld third patients. who had double H I A haploidelHical donors. were nO/lcomplialH. However. the other three of the first five were HLA mismatched. They·and [he more recently treated patients 6. 7. and 8 had at least four of the serious complications of immunosuppression listed in the footnote. Only patient 8 (whose transplantation was done in 1987) had rejection with weaning. This was promptly diagnosed and easily reversed.
Rejection after drug discontinuance
The benefits of weaning from immunosuppressive therapy for organ recipients are obvious. However. it is equally importam to recognize that there was a 30% overall risk for rejection in the prospective liver trial. Successful weaning was achieved consistently only in patic;nts who were weaned from an azathioprine-prednisone regimen or from monotherapy with tacrolimus. s ·} When weaning failed. rejection was diagnosed 1 to 29 months after the beginning of weaning (see Fig. 35-8) . Rejection was classed histopathologically as minimal to mild in 20 of 24 patients and moderate or severe in the other four.
Restoration of the previous baseline immunosuppression was the only adjustment required in most t.:ases. but the four patients with moderate or severe rejet.:tion required rescue treatment with tacrolimus; one patient who required rescue treatment became jaundiced with a peak bilirubin of 12 mg%. Although no patients or grafts were lost in our rrial, Sandborn et aiM encountered rejection in 6 of 12 patients being rapidly weaned from cyclosporine-based triple drug therapy only 3 years after transplantation; two of the six died. It would be foolhardy to ignore such a warning.
Bone marrow transplantation
After the discovery that successful whole organ transplantation was associated with spontaneous chimerism. it was realized that the perceived schism between the bone marrow and whole organ transplantation fields reflected entrenched differences in treatment strategy (Fig. 35-9 ). The mutually censoring immunologic limbs were left intact with organ transplantation. whereas the recipient limb was deliberately removed (cycoablation) in preparation for bone marrow grafting procedures. Although it had long been assumed thac che entire recipient immune system had been eliminated with successful bone marrow transplantation (see Fig. 35-1 . BJ. a rrace population of recipient leukocyces has been detected with sensitive techniques in the blood of almost all such patients. 57. 1 14 These bone marrow recipients were in fact mirror images of those successfully bearing whole organ allografts. the difference being chat their own racher chan donor leukocytes constituted the trace population. Under both circumstances. other such findings as the appearance of veco and suppressor cells. enhancing antibodies. and changes in cycokine profile could be construed as by-products of and accessory co the seminal event of the mutual cell engagement (see Fig. 35-\' C and D) .
ORGAN PRESERVATION Procurement
The breakthroughs of the early 1960s rim made transplantation clinically practical were so unexpected that almost no formal preparation had been made to preserve the transplanted organs. Cardiac surgeons had used hypothermia for open-heart operations from 1950 onward and knew that ischemic damage below the level of aortic cross-clamping could be reduced by cooling the subdiaphagmatic organs. 55 [n an early report.
Lillehei et a1 39 immersed intestines in iced saline before autotransplantation. In Boscon. Sicular and Moore 69 reported greatly slowed enzyme degradation in cold slices of liver. Despite this awareness. kidneys from identical twins were routinely transplanted with no protection from warm ischemia during organ transfer. Until 1963. the only attempt to cool kidney allografts was by the potentially dangerous practice used by cardiac surgeons of immersing the living volunteer donor in a bathtub of ice water (rotal body hyporhermia).79 This cumbersome method of cooling was quickly replaced by infusion of chilled solutions into the renal artery after donor nephrectomy.7.1 exploiting a principle of core (transvascular) cooling that had been standardized several years earlier for experimental liver transplantation. K6 Core cooling in silll. which is currently the first critical step in the preservation of all cadaveric whole organs. is done with variations of the technique described in 1963 by Marchioro et al 4l and was lIsed clinically long before the acceptance of brain death criteria which now permits ill Jim cooling to be undertaken 7~ (Fig. 35-10 ). Ackerman and Snell l and Merkel et al~K popularized in Silll cooling of cadavc:ric kidneys with simple in- fusion of cold electrolyte solutions into the donor femoral artery or distal aorta. Procurement techniques were eventually perfected and allowed removal of all thoracic and abdominal organs. induding the liver. without jeopardizing any of the individual organs (Fig. 35-t 
Extended Preservation
Continuous vascular perfusion
In rhe first clinical applicarion of continuous vascular perfusion. Marchioro et aI 42 used a convenrional hearr-Iung machine and heat exchanger to continuously perfuse and cool all major organs (see Fig. 35-10 ). Efforts to continuously perfuse isolated organs proved to be more difficult. For renal allografts. Ackerman and Barnard I used a normothermic perfusate primed with blood and oxygenated wirhin a hyperbaric oxygen chamber. The perfusate was directed into the renal artery. Brettschneider et al l5 modified the appararus and were able ro preserve canine livers for 2 days. an unprecedented feat ar the rime. When Belzer er allo eliminated rhe hemoglobin and hyperbaric chamber components. their asanguinous hyporhermic perfusion rechnique was immediarely accepred for clinical renal rransplantar ion bur rhen slowly abandoned in mosr cenrers when ir was learned rhar rhe quality of 2-day preservation was not markedly better than thar of simpler and cheaper infusion and slush methods (see below). However. refinement of perfusion techniques may someday permit true organ banking. 
Static preservation
TISSUE TYPING
Antigen Matching
The fIrst prospective antigen matching rrials were begun in 1964
hy Terasaki 1<,. in collaboration with the University of Colorado kidney transplantation team. Although the value of this serologic technology was demonstrable when the kidney donor was a highly compatible family member (the perfect match),?3 lesser degrees of matching correlated poorly with renal tramplamation outcome.· The reason for this paradox were inexplicable until the discovery of recipient chimerism. Ironically, the belief that matching should be a prime determinant of success resulted in its use as an overriding factor for the allocation of cadaver kidneys in the United States. The propriety of this kidney allocation policy has been repeatedly challenged on ethical as well as sciemific grounds for a quarrel' of a century. Those in favor of its perpetuation cite multicenter case compilations in the United States and Europe showing a small gain in allograft survival with histocompatible kidneys, whereas many of the individual contributing cemers see no such trend in their own experience. 27 . 43, 63, 100 In a compelling recent study, Terasaki et al , 02 reported that early survival and the subsequent half-life of kidneys from randomly matched living unrelated donors was identical to that of parent-offspring (one haplotype matched) grafts.
In addition ro this hammerblow (0 matching, Gjenson, Cecka, and T erasaki l () have nmed that tacrolimus-based immunosuppression improved cadaver kidney graft survival for more than any degree of matching, including perfect compatibiliry. With tacrolimus, the projected half-life of cadaver kidneys was (Wice that achievable with any previously available immunosuppressive regimen, including those based on cyclosporine (14 versus 7 years). These findings were consistem with those in single-center 'OH and multicenter liver transplantation trials.H',X!.11 I The inescapable conclusion is that more effcctive immunosuppressive therapy rather than refinements in [issue matching and organ sharing will be rhe primary method or improving the results of whole organ transplantation.
Cross Matching
Allotranspla ntation
None of .he iml11unosuppressive measures available today can prevent iml11ediate destruction or kidneys and other kinds of organ grar.s in what has been called hyperacute rejection. This <':ol11plicllion was first seen widl the transplantation of kidneys frol11 AI\O-incompatible donors when they were placed in re-'1(..1,. 27, -11.1.,1, ' } I. 11111. II)~.
cipienrs wirh antidonor isoagglutinins. 74 After the description by Terasaki, Marchioro, and Stanl,,) 96 The grafts did not funcrion normally, but neither antibody nor cellmediated rejection could be definitively indicted as responsible.
Nevertheless, there was indirect evidence thar there had been a storm of inflammatory mediators, triggered by preformed xenospecific antibodies (principally IgM) and complement activation. The failures were similar to those that had occurred afrer clinical chimpanzee 61 and baboon renal rransplantation 88 a third of a century ago and the more recent Baby Fae heart cransplamarion. 6 A new generation of complement inhibitors 3 or the much-publicized creation of transgenic animal donors whose organs contain transfected human complement regulatory genes4S.II~ may provide rhe missing piece in the treatment puzzle. No(Withstanding such hopes, the practical objecdve of clinical xenorransplantation remains elusive, even with the use of closely related species.
